Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin...

Full description

Bibliographic Details
Main Authors: Molina, Ana M., Ginsberg, Michelle S., Motzer, Robert J.
Format: Online
Language:English
Published: Springer US 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219862/
id pubmed-3219862
recordtype oai_dc
spelling pubmed-32198622011-12-09 Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib Molina, Ana M. Ginsberg, Michelle S. Motzer, Robert J. Original Paper A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib). Springer US 2010-08-10 2011-12 /pmc/articles/PMC3219862/ /pubmed/20697842 http://dx.doi.org/10.1007/s12032-010-9640-y Text en © Springer Science+Business Media, LLC 2010
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Molina, Ana M.
Ginsberg, Michelle S.
Motzer, Robert J.
spellingShingle Molina, Ana M.
Ginsberg, Michelle S.
Motzer, Robert J.
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
author_facet Molina, Ana M.
Ginsberg, Michelle S.
Motzer, Robert J.
author_sort Molina, Ana M.
title Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
title_short Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
title_full Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
title_fullStr Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
title_full_unstemmed Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
title_sort long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
description A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin (mTOR) inhibitor everolimus, initially randomized to placebo (but had disease progression after 3 months) and crossed over to everolimus at time of unblinding. The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).
publisher Springer US
publishDate 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219862/
_version_ 1611488832093421568

Similar Items